CTOs on the Move

Ritter Natural Sciences

www.lactagen.com

 
Ritter Natural Sciences is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.lactagen.com
  • 10100 Santa Monica Blvd Ste 410
    Los Angeles, CA USA 90067
  • Phone: 800.324.7965

Executives

Name Title Contact Details

Similar Companies

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

Immunization for Public Health (i4ph)

Immunization for Public Health (i4ph) is a Galveston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

California Cryobank Inc.

California Cryobank Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Los Angeles, CA. To find more information about California Cryobank Inc., please visit www.cryobank.com

Nkarta Therapeutics

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body.

Repertoire

Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.